Sort
4,870 grants matching “glp 1”
A novel vaccine against multidrug-resistant gonorrhea
$653,148Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R01 · FY2022 · AI
Pharmacogenetic discovery in the GRADE comparative effectiveness type 2 diabetes clinical trial
$652,262Jose Carlos Florez · Massachusetts General Hospital · R01 · FY2022 · DK
Increased Protein at Breakfast for Weight Management in Overweight Adolescents
$652,109Heather J Leidy · Purdue University · R01 · FY2018 · DK
PRESERVATION OF BETA CELL FUNCTION IN PREDIABETES: IGT AND IFG
$652,096Ralph A Defronzo · University Of Texas Hlth Science Center · R01 · FY2017 · DK
Novel Biguanides to Treat Type 2 Diabetes
$651,885Ken W Batchelor · Novatarg, Inc. · R44 · FY2015 · DK
Prostanoid modulators that reduce brain injury and inflammation after seizures
$651,488Raymond J Dingledine · Emory University · U01 · FY2008 · NS
RBP2 Biology and Pathobiology
$651,464William S Blaner · Columbia University Health Sciences · R01 · FY2025 · DK
GLP-1 analogue effects on food cues, stress, motivation for highly palatable foods, and weight
$651,452Ania Jastreboff · Yale University · R01 · FY2024 · DK
EGFRwt and EGFRvlll Dual-Specific Immunotoxin for Glioblastoma Multiforme
$651,410Darell D Bigner · Duke University · P01 · FY2015 · CA
Pharmacogenetic discovery in the GRADE comparative effectiveness type 2 diabetes clinical trial
$650,707Jose Carlos Florez · Massachusetts General Hospital · R01 · FY2023 · DK
PASSIVE IMMUNITY TO COCAINE USING NOVEL HUMAN ANTIBODIES
$650,000University Of Cincinnati · U19 · FY2003 · DA
Institute of Human Virology H3Africa Biorepository (I-HAB)
$650,000Alash'le G. Abimiku · Institute Of Human Virology · U24 · FY2020 · HG
A Hypoxia Activated HIF-1 &Inhibitor for Cancer Therapy
$649,996Prolx Pharmaceuticals Corporation · R44 · FY2005 · CA
A Hypoxia Activated HIF-1 &Inhibitor for Cancer Therapy
$649,618Prolx Pharmaceuticals Corporation · R44 · FY2003 · CA
Bumped-Kinase Inhibitor Drug Development for Toxoplasmosis
$649,614Wesley C Van Voorhis · University Of Washington · R01 · FY2023 · HD
Pre-Clinical and Clinical Studies of Cobinamide, A New Cyanide Detoxifying Agent
$648,900Gerry R Boss · University Of California, San Diego · U01 · FY2012 · NS
A Hypoxia Activated HIF-1 &Inhibitor for Cancer Therapy
$648,754Prolx Pharmaceuticals, Lp · R44 · FY2002 · CA
Iron Chelators Predicated on Desferrithiocin
$647,279Raymond J Bergeron · University Of Florida · R37 · FY2010 · DK
Targeting hepatic mitochondrial oxidation to treat NAFLD, NASH and type 2 diabetes
$647,207Gerald I Shulman · Yale University · R01 · FY2025 · DK
Validation of Novel Therapeutic Approach for Leptomeningeal Metastases
$646,349Aaron Richard McCabe · Minnetronix, Inc. · R42 · FY2019 · CA
Effect of Bariatric Surgery on Mechanisms of Type 2 Diabetes: The B2D Trial
$646,163John P. Kirwan · Cleveland Clinic Lerner Com-Cwru · R01 · FY2012 · DK
A phase I study of RNA-lipid particle vaccines for newly-diagnosed glioblastoma, IND19304 08/21/2020
$645,379Elias Sayour · University Of Florida · R01 · FY2025 · FD
Pharmacogenetics of the Response to a GLP1R Agonist
$645,147Amber L Beitelshees · University Of Maryland Baltimore · R01 · FY2024 · DK
Engineered Glucose Metabolism in Insulin Secreting Cells
$645,074Christopher B Newgard · Duke University · R01 · FY2023 · DK
Designed Antimalarial Agents Overcoming Chloroquine-Resistance
$644,773David H Peyton · Designmedix, Inc. · R42 · FY2010 · AI